Pre Exposure Prophylaxis News and Research

RSS

Chloroquine/hydroxychloroquine could treat COVID-19 infection

The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths, and a large number of open cases.

1 Dec 2020

HIV-related health services in Thailand during COVID-19 pandemic

Thailand's key population-led health services (KPLHS) are a hallmark of the success of the country's HIV response.

30 Nov 2020

Cabotegravir highly effective in preventing HIV among women

UNAIDS has been strongly encouraged by groundbreaking new study results showing that the antiretroviral medicine cabotegravir administered by an injection every two months – prevents HIV among women.

10 Nov 2020

Trial results show CAB LA is more effective in preventing HIV acquisition in women

The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.

10 Nov 2020

Hydroxychloroquine does not prevent COVID-19 in health care workers, trial shows

University of Minnesota Medical School physician researchers studied hydroxychloroquine as a treatment to prevent COVID-19 for those with high-risk for exposure to the virus - health care workers.

21 Oct 2020

Study explores women's interest in long-acting injectable PrEP to prevent HIV

Oral pre-exposure prophylaxis (PrEP) is a highly effective method of reducing risk for HIV, yet use of PrEP is uniformly low, especially among women.

22 Sep 2020

PrEP prescribing is not routine for many medical practitioners, study finds

Only about 54% of medical practitioners surveyed say they have prescribed pre-exposure prophylaxis, or PrEP, to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.

17 Sep 2020

State-level policies are crucial to HIV prevention efforts

HIV prevention remains a public health priority in the United States. Pre-exposure prophylaxis (PrEP) is a drug regimen recommended for individuals who have engaged in behaviors that place them at elevated risk for HIV.

9 Sep 2020

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.

31 Aug 2020

Short-term PrEP use could be a successful way to prevent HIV spread in at-risk men on vacation

Men at particular risk for HIV are very likely to consistently take prevention medication during vacations when their odds of contracting the virus are higher, according to a new study led by scientists at the University of Pittsburgh Graduate School of Public Health, The Fenway Institute and Harvard University.

12 Aug 2020

Clinical trials of hydroxychloroquine in COVID-19 outpatients reported as safe

According to new research, the use of hydroxychloroquine among outpatients in clinical trials, without high-risk factors for cardiac arrhythmia, is safe.

27 Jul 2020

Face masks do not lead to false sense of security, shows study

Existing limited evidence suggests that wearing face coverings to protect against COVID-19 does not lead to a false sense of security and is unlikely to increase the risk of infection through wearers foregoing other behaviours such as good hand hygiene, say researchers from the University of Cambridge and King's College London.

27 Jul 2020

Monthly vaginal ring for HIV prevention receives positive opinion from EMA

The International Partnership for Microbicides today welcomed a positive opinion from the European Medicines Agency on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV-1 infection.

24 Jul 2020

Monthly vaginal ring moves one step closer to becoming a new HIV prevention method

A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.

24 Jul 2020

NIH study: Long-acting form of HIV prevention drug more effective than daily oral pill

A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health.

7 Jul 2020

Pre Exposure Prophylaxis News and Research

Chloroquine/hydroxychloroquine could treat COVID-19 infection

HIV-related health services in Thailand during COVID-19 pandemic

Cabotegravir highly effective in preventing HIV among women

Trial results show CAB LA is more effective in preventing HIV acquisition in women

Hydroxychloroquine does not prevent COVID-19 in health care workers, trial shows

Study explores women's interest in long-acting injectable PrEP to prevent HIV

PrEP prescribing is not routine for many medical practitioners, study finds

State-level policies are crucial to HIV prevention efforts

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

Short-term PrEP use could be a successful way to prevent HIV spread in at-risk men on vacation

Clinical trials of hydroxychloroquine in COVID-19 outpatients reported as safe

Face masks do not lead to false sense of security, shows study

Monthly vaginal ring for HIV prevention receives positive opinion from EMA

Monthly vaginal ring moves one step closer to becoming a new HIV prevention method

NIH study: Long-acting form of HIV prevention drug more effective than daily oral pill

Incarceration and police discrimination may worsen health of Black sexual minority men

HVTN and HPTN initiate first clinical trial in response to COVID-19

Newly developed laboratory model helps reveal how HIV infection affects the brain

PrEP drug levels found to lower among pregnant African adolescent girls and young women

HHS removed images of condoms from HIV/AIDS awareness fliers

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News